Biocartis Poised for 2014 Commerical Launch with EUR 30 Million Series E Equity Fundraising

Mechelen, Belgium And Lausanne, Switzerland (ots/PRNewswire) -

Biocartis, a molecular diagnostics company developing and
commercializing innovative, easy to use platforms and clinically
relevant assays, announced today the completion of an EUR 30 million
Series E equity fundraising. The additional capital will be used to
validate Biocartis' molecular diagnostics platform Idylla[TM]and its
first assay and to continue the development of a range of assays,
primarily in the oncology field. Biocartis is now in pole position to
unroll an ambitious commercialization plan in 2014.

This series E round was entirely subscribed by the existing
shareholders such as RMM (Rudi Marien), Debiopharm DiagnosticsSA, PMV
Tina Fund, Valiance, Johnson & Johnson Development Corporation,
Philips, the Wellcome Trust, Petercam, the family offices of Dr. Paul
Janssen, Luc Verelst, Rudi Pauwels (founder of Biocartis) and some
smaller shareholders, including some employees.

Hilde Windels, CFO of Biocartis, commented: "We believe the
successful completion of this fundraise is again a testimony to the
quality of Biocartis' technology, its leading position, its promise
to provide the tools for true personalized medicine in an
exponentially growing market. Our molecular diagnostics platform
Idylla[TM][1] truly meets the need of pathologists and key clinicians
who recognize the platform as being rapid and easy-to-use, with a
high level of standardization. We are delighted that our existing
shareholders continue to support Biocartis' progress, and look
forward to putting these resources to work to advance our vision of
becoming a fully integrated global diagnostics company."

Biocartis' flagship platform Idylla[TM] and the BRAF cancer assay
are expected to be launched in the second half of 2014. Idylla[TM] is
a compact and scalable molecular diagnostics platform that allows
assays to be performed anywhere, anytime without the need for a
specialist laboratory environment and trained technicians. Idylla[TM]
rapidly detects biomarkers in cancer samples, amongst other clinical
patient samples, with a much higher sensitivity as compared to
standard diagnostic assays and standard sequencing.

ots Originaltext: Biocartis
Im Internet recherchierbar: http://www.presseportal.de

Contact:
Contact: Hilde Windels, CFO, Phone: +32 15 632 600 (Mechelen),
hwindels@biocartis.com